Tag Archives: Politics

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Posted in Guest Blog, healthcare, Legal, Market Access, pricing, R&D, Regulatory, Sales, Strategy | Also tagged , , , , , , , | 1 Comment

No 'One Drug Per Therapeutic Class' for Congress

by Tom Norton As many of you may recall, earlier this year I commented on a section of the new Obamacare law that directed Members of Congress and their staffs to participate in the new healthcare program, effective January 1, 2014.  The theory was that if Congress mandated Obamacare for all Americans, then Members of […]
Posted in Guest Blog, healthcare, Legal, Regulatory, Strategy | Also tagged , , , , , , , , | Leave a comment

Congress 'Tip Toes' Around Obamacare

by Tom Norton Of the many issues involved with the actual implementation of the 2010 Affordable Care Act, aka, “Obamacare”, few are more intriguing to me than those that personally impact Members of Congress (MOCs).  Here’s a good example of what I’m talking about — Today, on Capitol Hill, MOCs, along with thousands of their […]
Posted in Guest Blog, healthcare, Legal, Strategy | Also tagged , , , , , , , | 3 Comments

Sequestration: How Big a Hit for FDA, Research and Pharma?

The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality […]
Posted in FDA, healthcare, leadership, Legal, R&D | Also tagged , , , , , , | Leave a comment

Clayton Christensen on the Future of Pharma

A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.
Posted in Biotech, Events, FDA, healthcare, IP, leadership, People, R&D, Regulatory, Safety, Technology, Uncategorized | Also tagged , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta